Convenia Injection 80 mg/ml (10ml single injection)

Convenia is presented as a vial of lyophilised powder containing 852 mg cefovecin (as sodium salt), 19.17 mg methyl parahydroxybenzoate and 2.13 mg propyl parahydroxybenzoate, supplied with a vial of diluent containing 13 mg/ml benzyl alcohol and 10.8 ml water for injections. When reconstituted according to label instructions, the solution for injection contains:
80.0 mg/ml cefovecin (as sodium salt)
1.8 mg/ml methyl parahydroxybenzoate
0.2 mg/ml propyl parahydroxybenzoate
12.3 mg/ml benzyl alcohol
Convenia is indicated for the following:
Dogs:
For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus intermedius, haemolytic Streptococci, Escherichia coli and/or Pasteurella multocida.
For the treatment of urinary tract infections associated with Escherichia coli and/or Proteus spp.
Cats:
For the treatment of skin and soft tissue abscesses and wounds associated with Pasteurella multocida, Fusobacterium spp., Bacteroides spp., Prevotella oralis, haemolytic Streptococci and/or Staphylococcus intermedius.
For the treatment of urinary tract infections associated with Escherichia coli.
Visit www.myvetmeds.co.uk / cat / antibiotics-cat / convenia-injection-80-mg-ml.htm
Product Description
About Convenia Injection 80 mg/ml (10ml single injection)
Convenia is presented as a vial of lyophilised powder containing 852 mg cefovecin (as sodium salt), 19.17 mg methyl parahydroxybenzoate and 2.13 mg propyl parahydroxybenzoate, supplied with a vial of diluent containing 13 mg/ml benzyl alcohol and 10.8 ml water for injections. When reconstituted according to label instructions, the solution for injection contains:
80.0 mg/ml cefovecin (as sodium salt)
1.8 mg/ml methyl parahydroxybenzoate
0.2 mg/ml propyl parahydroxybenzoate
12.3 mg/ml benzyl alcohol
Convenia is indicated for the following:
Dogs:
For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus intermedius, haemolytic Streptococci, Escherichia coli and/or Pasteurella multocida.
For the treatment of urinary tract infections associated with Escherichia coli and/or Proteus spp.
Cats:
For the treatment of skin and soft tissue abscesses and wounds associated with Pasteurella multocida, Fusobacterium spp., Bacteroides spp., Prevotella oralis, haemolytic Streptococci and/or Staphylococcus intermedius.
For the treatment of urinary tract infections associated with Escherichia coli.
Please note: images are for illustration purposes only and pack sizes/strengths and new packaging styles may not be reflected in the image shown.
Directions For Use
Directions for Use
The recommended dose rates are :15 mg/kg bodyweight febantel,
Active Ingredient
Convenia Injection 80 mg/ml (10ml single injection) ingredients
Convenia is presented as a vial of lyophilised powder containing 852 mg cefovecin (as sodium salt), 19.17 mg methyl parahydroxybenzoate and 2.13 mg propyl parahydroxybenzoate, supplied with a vial of diluent containing 13 mg/ml benzyl alcohol and 10.8 ml water for injections. When reconstituted according to label instructions, the solution for injection contains:
80.0 mg/ml cefovecin (as sodium salt)
1.8 mg/ml methyl parahydroxybenzoate
0.2 mg/ml propyl parahydroxybenzoate
12.3 mg/ml benzyl alcohol
Side Effects
Side effects of Convenia Injection 80 mg/ml (10ml single injection)
Do not use in case of hypersensitivity to cephalosporin or penicillin antibiotics.
Do not use in small herbivores (including guinea pigs and rabbits).
Do not use in dogs and cats less than 8 weeks old.
On very rare occasions gastrointestinal signs, including emesis and/or diarrhoea have been observed.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
It is prudent to reserve third generation cephalosporins for the treatment of clinical conditions, which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials or first generation cephalosporins. Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies.
The safety of Convenia in dogs and cats has not been established during pregnancy and lactation. Treated animals should not be used for breeding for 12 weeks after the last administration.
The safety of Convenia has not been assessed in animals suffering from severe renal dysfunction.
Caution should be exercised in patients that have previously shown hypersensitivity reactions to cefovecin, other cephalosporins, penicillins, or other drugs. If an allergic reaction occurs, no further administrations of cefovecin should be administered and appropriate therapy for beta-lactam hypersensitivity should be instituted. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamine, corticosteroids, and airway management, as clinically indicated. Veterinarians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.
Concurrent use of other substances that have a high degree of protein binding (e.g. furosemide, ketoconazole, or non-steroidal anti-inflammatory drugs (NSAIDs)) may compete with cefovecin binding and thus may cause adverse effects.
Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young dogs. Slight and transient injection site swellings were observed after the first and second administration. A single administration of 22.5 times the recommended dose caused transient oedema and discomfort at the injection site. Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young cats. A single administration of 22.5 times the recommended dose caused transient oedema and discomfort at the injection site.
User warnings:
Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross sensitivity to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.
Do not handle this product if you know you are sensitised or if you have been advised not to work with such preparations.
Handle this product with care to avoid exposure, taking all recommended precautions.
If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention. If you know you are allergic to penicillins or cephalosporins, avoid contact with contaminated litter. In the event of contact, wash skin with soap and water.
Additional Data
Convenia Injection 80 mg/ml (10ml single injection) specification
| Specification: | Detail: |
|---|---|
| Pack Size: | 10ml single injection |
| Brands: | Pfizer |
| Product Form: | injection |
| External Link: | http://www.noahcompendium.co.uk/Pfizer_Limited/Convenia_80_mg_ml_powder_and_solvent_for_solution_for_injection_for_dogs_and_cats/-43046.html |
| Strength/Size: | 80 mg/ml |

















